Multiple Myeloma Coverage from Every Angle
Editors:
Shaji K. Kumar, MD
Prashant Kapoor, MD, FACP
Advertisement
Advertisement

Available Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials
Center for Immunotherapy Clinical Research Trials
City of Hope Comprehensive Cancer Center
ClinicalTrials.gov Immunotherapy
Dana-Farber Cancer Institute
Duke Cancer Institute
Fox Chase Cancer Center
Fred & Pamela Buffett Cancer Center
Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance
Huntsman Cancer Institute at the University of Utah
Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center
Mayo Clinic Cancer Center
Memorial Sloan Kettering Cancer Center
Moffitt Cancer Center
A Phase 1/2 FIH Study of REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma
Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Patients With Relapsed or Refractory Multiple Myeloma
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Roswell Park Cancer Institute
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The University of Texas MD Anderson Cancer Center
UC San Diego Moores Cancer Center
UCSF Helen Diller Family Comprehensive Cancer Center
University of Colorado Cancer Center
University of Michigan Comprehensive Cancer Center
University of Wisconsin Carbone Cancer Center
Vanderbilt-Ingram Cancer Center
Yale Cancer Center / Smilow Cancer Hospital
Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.